420 related articles for article (PubMed ID: 1603139)
1. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension.
Rich S; Kaufmann E; Levy PS
N Engl J Med; 1992 Jul; 327(2):76-81. PubMed ID: 1603139
[TBL] [Abstract][Full Text] [Related]
2. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension.
Sitbon O; Humbert M; Jaïs X; Ioos V; Hamid AM; Provencher S; Garcia G; Parent F; Hervé P; Simonneau G
Circulation; 2005 Jun; 111(23):3105-11. PubMed ID: 15939821
[TBL] [Abstract][Full Text] [Related]
3. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension.
McLaughlin VV; Genthner DE; Panella MM; Rich S
N Engl J Med; 1998 Jan; 338(5):273-7. PubMed ID: 9445406
[TBL] [Abstract][Full Text] [Related]
4. Effects of adenosine in combination with calcium channel blockers in patients with primary pulmonary hypertension.
Inbar S; Schrader BJ; Kaufmann E; Vestal RE; Rich S
J Am Coll Cardiol; 1993 Feb; 21(2):413-8. PubMed ID: 8426006
[TBL] [Abstract][Full Text] [Related]
5. Treatment of mild-to-moderate hypertension with calcium channel blockers: a multicentre comparison of once-daily nifedipine GITS with once-daily amlodipine.
Kes S; Caglar N; Canberk A; Deger N; Demirtas M; Dortlemez H; Kiliccioglu B; Kozan O; Ovunc K; Turkoglu C
Curr Med Res Opin; 2003; 19(3):226-37. PubMed ID: 12803737
[TBL] [Abstract][Full Text] [Related]
6. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation.
Conte JV; Gaine SP; Orens JB; Harris T; Rubin LJ
J Heart Lung Transplant; 1998 Jul; 17(7):679-85. PubMed ID: 9703232
[TBL] [Abstract][Full Text] [Related]
7. Differences in the acute pulmonary vascular effects of oxygen with nitric oxide and diltiazem: implications for the long-term treatment of pulmonary arterial hypertension.
Day RW
Congenit Heart Dis; 2013; 8(1):71-7. PubMed ID: 22891699
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of the effects of vasodilator therapy in primary pulmonary hypertension. Experience in 7 cases].
Lanzarini L; Gavazzi A; Mussini A; Graziano G; Campana C; Bargiggia G; Angoli L; Aimè E; Arbustini E; Montemartini C
G Ital Cardiol; 1990 Feb; 20(2):114-22. PubMed ID: 2328864
[TBL] [Abstract][Full Text] [Related]
9. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy.
Rich S; Brundage BH
Circulation; 1987 Jul; 76(1):135-41. PubMed ID: 2954725
[TBL] [Abstract][Full Text] [Related]
10. [Therapy of primary pulmonary arterial hypertension: current status].
Solèr M
Schweiz Med Wochenschr; 1994 Oct; 124(39):1701-7. PubMed ID: 7939536
[TBL] [Abstract][Full Text] [Related]
11. Rapid large artery remodeling following the administration and withdrawal of calcium channel blockers in spontaneously hypertensive rats.
Vaja V; Ochodnicky P; Krenek P; Klimas J; Bajuszova Z; Kyselovic J
Eur J Pharmacol; 2009 Oct; 619(1-3):85-91. PubMed ID: 19683522
[TBL] [Abstract][Full Text] [Related]
12. Invasive pharmacodynamic characterization of combined ibopamine and calcium blocker therapy for heart failure.
Munger MA; Nara AR; Pospisil RA; Stoddard GJ; Schleman M
Pharmacotherapy; 1993; 13(3):218-23. PubMed ID: 8100627
[TBL] [Abstract][Full Text] [Related]
13. [Survival--a question of active treatment. High-dose calcium blockers in pulmonary hypertension].
Husebye ES; Wibell L
Lakartidningen; 1994 Jun; 91(26-27):2573-5. PubMed ID: 8046974
[No Abstract] [Full Text] [Related]
14. N-terminal pro-brain natriuretic peptide as a diagnostic marker of early pulmonary artery hypertension in patients with systemic sclerosis and effects of calcium-channel blockers.
Allanore Y; Borderie D; Meune C; Cabanes L; Weber S; Ekindjian OG; Kahan A
Arthritis Rheum; 2003 Dec; 48(12):3503-8. PubMed ID: 14674001
[TBL] [Abstract][Full Text] [Related]
15. Role of calcium antagonists in the treatment of essential hypertension.
Klein W; Brandt D; Vrecko K; Härringer M
Circ Res; 1983 Feb; 52(2 Pt 2):I174-81. PubMed ID: 6831651
[TBL] [Abstract][Full Text] [Related]
16. [Favorable response of pulmonary hypertension in patients with chronic obstructive airway disease treated with diltiazem].
Gassner A
Schweiz Med Wochenschr; 1984 Mar; 114(10):332-7. PubMed ID: 6710104
[TBL] [Abstract][Full Text] [Related]
17. Hemodynamic effects of nifedipine in pulmonary hypertension.
Klugmann S; Salvi A; Fioretti P; Camerini F
G Ital Cardiol; 1982; 12(7):505-8. PubMed ID: 7169146
[TBL] [Abstract][Full Text] [Related]
18. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT).
Brown MJ; Castaigne A; de Leeuw PW; Mancia G; Rosenthal T; Ruilope LM
J Hypertens; 1998 Dec; 16(12 Pt 2):2113-6. PubMed ID: 9886905
[TBL] [Abstract][Full Text] [Related]
19. Vasodilatory treatment of pulmonary hypertension.
Widimský J
Eur J Respir Dis; 1986 Mar; 68(3):161-6. PubMed ID: 2870937
[TBL] [Abstract][Full Text] [Related]
20. Comparison of baseline characteristics and survival between patients with idiopathic and connective tissue disease-related pulmonary arterial hypertension.
Ruiz-Cano MJ; Escribano P; Alonso R; Delgado J; Carreira P; Velazquez T; Sanchez MA; Sáenz de la Calzada C
J Heart Lung Transplant; 2009 Jun; 28(6):621-7. PubMed ID: 19481024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
